AstraZeneca: Melanoma trials
The registry lists 20 Melanoma studies with AstraZeneca as lead sponsor. 2 are open to participants now and 3 have results posted.
Phase 1 11Phase 2 8Phase 3 1No phase 1(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- DESTINY-PANTUMOUR04RecruitingNCT07124000
- A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid TumorsRecruitingNCT07115043Phase 1/2
- A Study of Ceralasertib Monotherapy and Ceralasertib Plus Durvalumab in Patients With Melanoma and Resistance to PD-(L)1 InhibitionActive, not recruitingNCT05061134Phase 2Results posted
- Comparison of AZD6244 in Combination With Dacarbazine Versus (vs) Dacarbazine Alone in BRAF Mutation Positive Melanoma PatientsCompletedNCT00936221Phase 2Results posted
- A Rollover Study for Patients Who Received Tremelimumab in Other Protocols, to Allow the Patients Access to Tremelimumab Until This Agent Becomes Commercially Available or Development is Discontinued.CompletedNCT00378482Phase 2Results posted
- First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid TumoursCompletedNCT04504669Phase 1
- A Study to Assess the Safety, Tolerability and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid TumoursCompletedNCT02586987Phase 1
- Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib AloneCompletedNCT02027961Phase 1
- Study to Assess the Safety, Tolerability, and Pharmacokinetics of AMP-224 in Patients With Advanced CancerCompletedNCT01352884Phase 1
- Study to Assess the Effect of Dosing AZD6244 HydSulfate in the Presence and Absence of Food in Patients With Advanced Solid MalignanciesCompletedNCT00710515Phase 1
- A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)CompletedNCT00600496Phase 1
- A Study To Assess The Safety Of Administering CP-675,206 As A One Hour Infusion In Patients With Surgically Incurable Advanced MelanomaTerminatedNCT00585000Phase 1
- A Study to Assess the Safety and Pharmacokinetics of an Inhibitor of PARP in Combination With DacarbazineCompletedNCT00516802Phase 1
- Study to Compare Two Formulations of CP-675,206 Monoclonal AntibodyCompletedNCT00431275Phase 1
- Randomised Study to Compare the Efficacy of AZD6244 vs TMZCompletedNCT00338130Phase 2
- CP-675,206 Versus Either Dacarbazine Or Temozolomide In Patients Without Prior TherapyCompletedNCT00257205Phase 3
- Study of CP-675,206 in Refractory MelanomaCompletedNCT00254579Phase 2
- Study of the Tumor Saturation and Biological Activity of MEDI-522 (Abergrin) in Patients With Advanced Malignant MelanomaCompletedNCT00111696Phase 1
- CP-675,206 In Patients With Advanced MelanomaCompletedNCT00086489Phase 2
- Evaluating The Antitumor Activity Of MEDI-522 With Or Without Dacarbazine In Patients With Metastatic MelanomaCompletedNCT00066196Phase 2